|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||491.34 g·mol−1|
|3D model (JSmol)|
It was discovered at Hanmi; in August 2014 Hanmi exclusively licensed rights in China to the Chinese company Luye Pharma and in February 2015 Hanmi licensed rights in the rest of the world outside of South Korea to Spectrum.
As of 2016 Spectrum had started a Phase II trial of poziotinib a second-line treatment for breast cancer.
- "Poziotinib". AdisInsight. Retrieved 25 March 2017.
- Kim, Marie (4 July 2016). "Hanmi Pharmaceutical to Step Up R&D Investment to Further Develop Core Technologies". BusinessKorea.
- Roskoski R, Jr (September 2014). "ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors". Pharmacological Research. 87: 42–59. doi:10.1016/j.phrs.2014.06.001. PMID 24928736.
- "Poziotinib". NCI Drug Dictionary. Retrieved 25 March 2017.